Kiora Pharmaceuticals, Inc. (KPRX)
Recent Filing Index
| Form | Filed | Qtr End | F_Period | 8K: Earnings Release |
|---|---|---|---|---|
| 10-QLatest | Q2-2026 | 8-K (2026-08-07) · 99.1 | ||
| 10-Q | Q1-2026 | 8-K (2026-05-08) · 99.1 | ||
| 10-KLatest | FY-2025 | 8-K (2026-03-25) · 99.1 | ||
| 10-Q | Q3-2025 | 8-K (2025-11-07) · 99.1 | ||
| 10-Q | Q2-2025 | 8-K (2025-08-08) · 99.1 | ||
| 10-Q | Q1-2025 | 8-K (2025-05-09) · 99.1 | ||
| 10-K | FY-2024 | 8-K (2025-03-25) · 99.1 | ||
| 10-Q | Q3-2024 | 8-K (2024-11-08) · 99.1 | ||
| 10-Q | Q2-2024 | 8-K (2024-08-09) · 99.1 | ||
| 10-Q | Q1-2024 | 8-K (2024-05-10) · 99.1 | ||
| 10-K | FY-2023 | 8-K (2024-03-25) · 99.1 | ||
| 10-Q | Q3-2023 | 8-K (2023-11-09) · 99.1 |
Filing Summary
| Report Name | Notes | Fiscal Period (Annual) | Fiscal Period (Quarter) |
|---|---|---|
| Cover | ||
| Audit Information | — |
|
| Statements | ||
| Consolidated Balance Sheets | ||
| Consolidated Balance Sheets (P) | ||
| Condensed Consolidated Statements of Operations and Comprehensive (loss) Income | — |
|
| Consolidated Statements of Operations and Comprehensive Loss | ||
| Consolidated Statements of Operations and Comprehensive Income (loss) | ||
| Consolidated Statements of Stockholders' Equity | ||
| Consolidated Statements of Cash Flows | ||
| Consolidated Statements of Stockholders' Equity (P) | ||
| Notes | ||
| Accrued Collaboration Credit | — |
|
| Accrued Expenses | — |
|
| Balance Sheet Information | — |
|
| Business, Presentation and Recent Accounting Pronouncements | ||
| Capital Stock | ||
| Collaboration Agreements | — |
|
| Commitments and Contingencies | ||
| Cybersecurity Risk Management and Strategy Disclosure | — |
|
| Employee Benefit Plans | — |
|
| Equity Incentive Plan | — |
|
| Fair Value | — |
|
| Fair Value Disclosures | — |
|
| Income Taxes | — |
|
| Insider Trading Arrangements | ||
| Insider Trading Policies and Procedures | — |
|
| Intangible Assets and In-process R&d | ||
| Net (loss) Income Per Share | — |
|
| Net Income (loss) Per Share | — |
|
| Net Loss Per Share | — |
|
| Net Loss Per Share - Basic and Diluted | — |
|
| Pay Vs Performance Disclosure | ||
| Prepaid Collaboration Expenses | — |
|
| Prepaid Collaboration Expenses and Accrued Collaboration Credit | — |
|
| Prepaid Expenses and Other Current Assets | — |
|
| Property and Equipment | — |
|
| Related Party Transactions | — |
|
| Roll-forward of Toi Activity | ||
| Segment Information | ||
| Segment Reporting | — |
|
| Stock-based Compensation | — |
|
| Subsequent Events | ||
| Summary of Significant Accounting Policies | — |
|
| Warrants | ||